@article{5c28b4c4c8bd42a2b03cb41b0acc3e48,
title = "Systemic timolol exposure following topical application to infantile hemangiomas",
author = "{Pediatric Trials Network Steering Committee (See Acknowledgments for a listing of committee members.)} and Drolet, {Beth A.} and Felix Boakye-Agyeman and Barrie Harper and Kristen Holland and Andrew Lewandowski and Nicole Stefanko and Chiara Melloni and Gary Furda and Danny Benjamin and Edmund Capparelli and Kearns, {Gregory L.} and Paul, {Ian M.} and Christoph Hornik and Kelly Wade",
note = "Funding Information: Funding sources: Supported under National Institute of Child Health and Human Development contract HHSN275201000003I for the Pediatric Trials Network (principal investigator, Danny Benjamin). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Disclosure: Dr Drolet reports an investigator-initiated trial examining the safety of oral propranolol for treatment of infantile hemangioma that was sponsored by Pierre Fabre. She is owner and co-founder of Peds Derm Development Group, LLC. Dr Boakye-Agyeman, Mr Harper, Dr Holland, Dr Lewandowski, and Dr Stefanko have no conflicts of interest to disclose.",
year = "2020",
month = mar,
doi = "10.1016/j.jaad.2019.02.029",
language = "English (US)",
volume = "82",
pages = "733--736",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",
}